JP Morgan Chase
BCRX icon

JP Morgan Chase’s BioCryst Pharmaceuticals BCRX Stock Holding History

JP Morgan Chase’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14.6M Buy
1,541,978
+698,608
+83% +$5.43M ﹤0.01% 2353
2025
Q4 		$6.58M Sell
843,370
-289,007
-26% -$2.09M ﹤0.01% 3068
2025
Q3 		$8.59M Sell
1,132,377
-451,829
-29% -$3.76M ﹤0.01% 2864
2025
Q2 		$14.2M Buy
1,584,206
+518,623
+49% +$4.83M ﹤0.01% 2243
2025
Q1 		$7.99M Buy
1,065,583
+591,207
+125% +$4.77M ﹤0.01% 2751
2024
Q4 		$3.57M Sell
474,376
-102,753
-18% -$780K ﹤0.01% 3670
2024
Q3 		$4.39M Sell
577,129
-170,402
-23% -$1.3M ﹤0.01% 3311
2024
Q2 		$4.62M Buy
747,531
+478,455
+178% +$2.64M ﹤0.01% 3094
2024
Q1 		$1.37M Sell
269,076
-278,461
-51% -$1.57M ﹤0.01% 4119
2023
Q4 		$3.28M Sell
547,537
-60,978
-10% -$353K ﹤0.01% 3447
2023
Q3 		$4.31M Sell
608,515
-23,000
-4% -$165K ﹤0.01% 2944
2023
Q2 		$4.45M Buy
631,515
+31,698
+5% +$254K ﹤0.01% 2953
2023
Q1 		$5M Sell
599,817
-194,720
-25% -$1.87M ﹤0.01% 2816
2022
Q4 		$9.12M Buy
794,537
+20,334
+3% +$254K ﹤0.01% 2344
2022
Q3 		$9.76M Buy
774,203
+225,163
+41% +$2.9M ﹤0.01% 2161
2022
Q2 		$5.81M Buy
549,040
+348,759
+174% +$3.6M ﹤0.01% 2652
2022
Q1 		$3.26M Buy
200,281
+17,823
+10% +$286K ﹤0.01% 3361
2021
Q4 		$2.53M Sell
182,458
-3,625
-2% -$48K ﹤0.01% 3669
2021
Q3 		$2.67M Sell
186,083
-11,403
-6% -$180K ﹤0.01% 3542
2021
Q2 		$3.12M Buy
197,486
+33,518
+20% +$455K ﹤0.01% 3447
2021
Q1 		$1.67M Sell
163,968
-16,372
-9% -$169K ﹤0.01% 3852
2020
Q4 		$1.34M Sell
180,340
-7,784
-4% -$40.1K ﹤0.01% 3762
2020
Q3 		$722K Sell
188,124
-1,565
-0.8% -$6.71K ﹤0.01% 3813
2020
Q2 		$904K Buy
189,689
+33,154
+21% +$132K ﹤0.01% 3575
2020
Q1 		$313K Sell
156,535
-265,627
-63% -$731K ﹤0.01% 4071
2019
Q4 		$1.46M Sell
422,162
-377,812
-47% -$950K ﹤0.01% 3614
2019
Q3 		$2.29M Buy
799,974
+501,377
+168% +$1.56M ﹤0.01% 3328
2019
Q2 		$1.08M Sell
298,597
-19,532
-6% -$118K ﹤0.01% 3813
2019
Q1 		$2.59M Sell
318,129
-54,011
-15% -$462K ﹤0.01% 3156
2018
Q4 		$3M Sell
372,140
-11,421
-3% -$88.8K ﹤0.01% 2969
2018
Q3 		$2.93M Buy
383,561
+355,418
+1,263% +$2.39M ﹤0.01% 3178
2018
Q2 		$161K Buy
28,143
+8,416
+43% +$46.3K ﹤0.01% 4657
2018
Q1 		$94K Sell
19,727
-1,411
-7% -$7.25K ﹤0.01% 4605
2017
Q4 		$104K Buy
+21,138
New +$102K ﹤0.01% 4650
2017
Q3 		– Sell
-244,613
Closed -$1.36M – 4962
2017
Q2 		$1.36M Sell
244,613
-6,242
-2% -$38K ﹤0.01% 3267
2017
Q1 		$2.11M Buy
250,855
+237,466
+1,774% +$1.65M ﹤0.01% 3012
2016
Q4 		$85K Buy
+13,389
New +$69.7K ﹤0.01% 4439
2015
Q4 		– Sell
-53,901
Closed -$614K – 4689
2015
Q3 		$614K Sell
53,901
-227,799
-81% -$3.04M ﹤0.01% 3344
2015
Q2 		$4.21M Buy
+281,700
New +$3.2M ﹤0.01% 2499
2014
Q4 		– Sell
-36,520
Closed -$357K – 4222
2014
Q3 		$357K Buy
36,520
+10,898
+43% +$134K ﹤0.01% 3786
2014
Q2 		$326K Buy
25,622
+12,344
+93% +$120K ﹤0.01% 3248
2014
Q1 		$140K Buy
+13,278
New +$142K ﹤0.01% 3459
2013
Q3 		– Sell
-39,595
Closed -$61K – 4370
2013
Q2 		$61K Buy
+39,595
New +$68.3K ﹤0.01% 4248

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

JP Morgan Chase's BCRX Position: Q1 2026 in Review

JP Morgan Chase increased its BioCryst Pharmaceuticals (BCRX) stake by 83% in Q1 2026, buying an estimated $5.43M and bringing the position to 1,541,978 shares worth $14.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2353.

JP Morgan Chase first reported a position in BCRX in Q2 2013 and has held it in 43 quarters since. 301 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

  • JP Morgan Chase held 1,541,978 shares of BioCryst Pharmaceuticals worth $14.6M as of Q1 2026.
  • JP Morgan Chase bought 698,608 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $5.43M.
  • BioCryst Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #2353 holding.
  • JP Morgan Chase first reported a position in BioCryst Pharmaceuticals in Q2 2013 and has held it in 43 quarters since.
  • 301 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.